LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
• Adbry is the primary biologic launched by LEO Pharma in america and is predicted to ...
Read more